Interpace Biosciences Expects Q3 Revenue Growth Up to 14% Sequentially
Interpace Biosciences, Inc. (IDXG) expects third-quarter 2026 revenue to fall between $10.1 million and $10.4 million. The preliminary, unaudited figures represent a sequential rise of approximately 11% to 14% compared to the second quarter of 2026, and a year-over-year increase of roughly 15% to 18% compared to the third quarter of 2025.
The quarter-over-quarter expansion points to renewed demand momentum for the company following a slower top-line performance during the first half of the year. Shares traded down 6.47% at $5.518 alongside the revenue disclosure.
Investors will look for finalized results, as the preliminary revenue estimate remains subject to quarter-end closing procedures and review. A complete picture of performance will depend on upcoming details regarding profit margins, cash flow, and potential updates to the full-year 2026 outlook.
Key points
- Interpace Biosciences estimates preliminary Q3 2026 revenue between $10.1 million and $10.4 million.
- Projected revenue represents a sequential gain of 11% to 14% compared to Q2 2026.
- Compared to Q3 2025, revenue is expected to be up 15% to 18% year-over-year.
- The top-line growth marks an acceleration following a softer first half of 2026.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is Interpace Biosciences expected Q3 2026 revenue?
Interpace Biosciences expects preliminary Q3 2026 revenue to be between $10.1 million and $10.4 million, reflecting sequential growth of 11% to 14%.
How much did Interpace Biosciences revenue grow year over year?
The company's projected third-quarter 2026 revenue represents an increase of approximately 15% to 18% compared to the third quarter of 2025.
Are Interpace Biosciences Q3 2026 financial results finalized?
No, the figures are preliminary and unaudited, subject to standard quarter-end closing procedures and final review.